Trial · NCT03913221
Adverse events32
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 32
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Acute Kidney Injury | Renal and urinary disorders | Low Dose Caffeine (5 mg/kg) | 2 | 9 | 2 |
| other | Acute Kidney Injury | Renal and urinary disorders | High Dose Caffeine (10 mg/kg) | 1 | 8 | 1 |
| other | Hepatic Dysfunction | Hepatobiliary disorders | Low Dose Caffeine (5 mg/kg) | 2 | 9 | 2 |
| other | Hepatic Dysfunction | Hepatobiliary disorders | High Dose Caffeine (10 mg/kg) | 0 | 8 | 0 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Low Dose Caffeine (5 mg/kg) | 5 | 9 | 5 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | High Dose Caffeine (10 mg/kg) | 2 | 8 | 2 |
| other | Pulmonary Hypertension | Respiratory, thoracic and mediastinal disorders | Low Dose Caffeine (5 mg/kg) | 1 | 9 | 1 |
| other | Pulmonary Hypertension | Respiratory, thoracic and mediastinal disorders | High Dose Caffeine (10 mg/kg) | 0 | 8 | 0 |
| other | Hypotension | Vascular disorders | Low Dose Caffeine (5 mg/kg) | 1 | 9 | 1 |
| other | Hypotension | Vascular disorders | High Dose Caffeine (10 mg/kg) | 1 | 8 | 1 |
| other | Supraventricular Tachycardia | Respiratory, thoracic and mediastinal disorders | Low Dose Caffeine (5 mg/kg) | 1 | 9 | 1 |
| other | Supraventricular Tachycardia | Respiratory, thoracic and mediastinal disorders | High Dose Caffeine (10 mg/kg) | 0 | 8 | 0 |
| other | Subcutaneous Fat Necrosis | Skin and subcutaneous tissue disorders | Low Dose Caffeine (5 mg/kg) | 1 | 9 | 1 |
| other | Subcutaneous Fat Necrosis | Skin and subcutaneous tissue disorders | High Dose Caffeine (10 mg/kg) | 0 | 8 | 0 |
| other | Hypertension | Vascular disorders | Low Dose Caffeine (5 mg/kg) | 1 | 9 | 1 |
| other | Hypertension | Vascular disorders | High Dose Caffeine (10 mg/kg) | 0 | 8 | 0 |
| other | Disseminated Intrvascular Coagulopathy | Hepatobiliary disorders | Low Dose Caffeine (5 mg/kg) | 1 | 9 | 1 |
| other | Disseminated Intrvascular Coagulopathy | Hepatobiliary disorders | High Dose Caffeine (10 mg/kg) | 0 | 8 | 0 |
| other | Hypoglycemia | Metabolism and nutrition disorders | Low Dose Caffeine (5 mg/kg) | 2 | 9 | 2 |
| other | Hypoglycemia | Metabolism and nutrition disorders | High Dose Caffeine (10 mg/kg) | 1 | 8 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03913221/events